Defining the clinical need and indications: Who are the right patients for transcatheter mitral valve replacement

Heike Baumgarten, John J. Squiers, Mani Arsalan, John M. Dimaio, Michael J. Mack

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Mitral regurgitation (MR) can be divided into two major etiologies, primary and secondary MR. Primary MR, also termed degenerative or organic MR, is a disease of the valve itself and is treated routinely by surgical repair in all but prohibitive risk patients. In these patients, transcatheter repair techniques, including edge to edge repair with the MitraClip device have been largely successful and widely adopted. Transcatheter placement of artificial chords has also been performed. The potential role for transcatheter mitral valve replacement (TMVR) in primary MR will likely be quite limited. Secondary or functional MR is due to a disease of the left ventricle and not the valve itself. The MR is a result of dilation of the left ventricle causing distraction of the papillary muscles with tethering of the mitral leaflets and lack of leaflet coaptation. Medical therapy is the mainstay treatment, with resynchronization used in appropriate patients. Surgical repair, usually with an undersized annuloplasty, is used in a limited number of patients. Transcatheter edge to edge repair is used extensively outside the US in secondary MR and is the subject of a pivotal trial in the US. However, it is in this group of patients with secondary MR that there is the largest clinical unmet need and, hence, the greatest potential opportunity for TMVR. At least ten TMVR platforms are in early feasibility, first in human, or preclinical trial stages. Four devices have cumulative early human experience in <100 patients. In this article, we discuss those patients most likely to benefit from TMVR and detail lessons learned from the first human studies regarding patient selection.

Original languageEnglish (US)
Pages (from-to)352-359
Number of pages8
JournalJournal of Cardiovascular Surgery
Volume57
Issue number3
StatePublished - Jun 1 2016

Fingerprint

Mitral Valve Insufficiency
Patient Rights
Mitral Valve
Heart Ventricles
Equipment and Supplies
Papillary Muscles
Patient Selection
Dilatation
Therapeutics

Keywords

  • Anatomy
  • Mitral valve insufficiency
  • Surgical procedures, operative

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Baumgarten, H., Squiers, J. J., Arsalan, M., Dimaio, J. M., & Mack, M. J. (2016). Defining the clinical need and indications: Who are the right patients for transcatheter mitral valve replacement. Journal of Cardiovascular Surgery, 57(3), 352-359.

Defining the clinical need and indications : Who are the right patients for transcatheter mitral valve replacement. / Baumgarten, Heike; Squiers, John J.; Arsalan, Mani; Dimaio, John M.; Mack, Michael J.

In: Journal of Cardiovascular Surgery, Vol. 57, No. 3, 01.06.2016, p. 352-359.

Research output: Contribution to journalReview article

Baumgarten, H, Squiers, JJ, Arsalan, M, Dimaio, JM & Mack, MJ 2016, 'Defining the clinical need and indications: Who are the right patients for transcatheter mitral valve replacement', Journal of Cardiovascular Surgery, vol. 57, no. 3, pp. 352-359.
Baumgarten, Heike ; Squiers, John J. ; Arsalan, Mani ; Dimaio, John M. ; Mack, Michael J. / Defining the clinical need and indications : Who are the right patients for transcatheter mitral valve replacement. In: Journal of Cardiovascular Surgery. 2016 ; Vol. 57, No. 3. pp. 352-359.
@article{c14c7927afd84542bccd01a10bd0df89,
title = "Defining the clinical need and indications: Who are the right patients for transcatheter mitral valve replacement",
abstract = "Mitral regurgitation (MR) can be divided into two major etiologies, primary and secondary MR. Primary MR, also termed degenerative or organic MR, is a disease of the valve itself and is treated routinely by surgical repair in all but prohibitive risk patients. In these patients, transcatheter repair techniques, including edge to edge repair with the MitraClip device have been largely successful and widely adopted. Transcatheter placement of artificial chords has also been performed. The potential role for transcatheter mitral valve replacement (TMVR) in primary MR will likely be quite limited. Secondary or functional MR is due to a disease of the left ventricle and not the valve itself. The MR is a result of dilation of the left ventricle causing distraction of the papillary muscles with tethering of the mitral leaflets and lack of leaflet coaptation. Medical therapy is the mainstay treatment, with resynchronization used in appropriate patients. Surgical repair, usually with an undersized annuloplasty, is used in a limited number of patients. Transcatheter edge to edge repair is used extensively outside the US in secondary MR and is the subject of a pivotal trial in the US. However, it is in this group of patients with secondary MR that there is the largest clinical unmet need and, hence, the greatest potential opportunity for TMVR. At least ten TMVR platforms are in early feasibility, first in human, or preclinical trial stages. Four devices have cumulative early human experience in <100 patients. In this article, we discuss those patients most likely to benefit from TMVR and detail lessons learned from the first human studies regarding patient selection.",
keywords = "Anatomy, Mitral valve insufficiency, Surgical procedures, operative",
author = "Heike Baumgarten and Squiers, {John J.} and Mani Arsalan and Dimaio, {John M.} and Mack, {Michael J.}",
year = "2016",
month = "6",
day = "1",
language = "English (US)",
volume = "57",
pages = "352--359",
journal = "Journal of Cardiovascular Surgery",
issn = "0021-9509",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Defining the clinical need and indications

T2 - Who are the right patients for transcatheter mitral valve replacement

AU - Baumgarten, Heike

AU - Squiers, John J.

AU - Arsalan, Mani

AU - Dimaio, John M.

AU - Mack, Michael J.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Mitral regurgitation (MR) can be divided into two major etiologies, primary and secondary MR. Primary MR, also termed degenerative or organic MR, is a disease of the valve itself and is treated routinely by surgical repair in all but prohibitive risk patients. In these patients, transcatheter repair techniques, including edge to edge repair with the MitraClip device have been largely successful and widely adopted. Transcatheter placement of artificial chords has also been performed. The potential role for transcatheter mitral valve replacement (TMVR) in primary MR will likely be quite limited. Secondary or functional MR is due to a disease of the left ventricle and not the valve itself. The MR is a result of dilation of the left ventricle causing distraction of the papillary muscles with tethering of the mitral leaflets and lack of leaflet coaptation. Medical therapy is the mainstay treatment, with resynchronization used in appropriate patients. Surgical repair, usually with an undersized annuloplasty, is used in a limited number of patients. Transcatheter edge to edge repair is used extensively outside the US in secondary MR and is the subject of a pivotal trial in the US. However, it is in this group of patients with secondary MR that there is the largest clinical unmet need and, hence, the greatest potential opportunity for TMVR. At least ten TMVR platforms are in early feasibility, first in human, or preclinical trial stages. Four devices have cumulative early human experience in <100 patients. In this article, we discuss those patients most likely to benefit from TMVR and detail lessons learned from the first human studies regarding patient selection.

AB - Mitral regurgitation (MR) can be divided into two major etiologies, primary and secondary MR. Primary MR, also termed degenerative or organic MR, is a disease of the valve itself and is treated routinely by surgical repair in all but prohibitive risk patients. In these patients, transcatheter repair techniques, including edge to edge repair with the MitraClip device have been largely successful and widely adopted. Transcatheter placement of artificial chords has also been performed. The potential role for transcatheter mitral valve replacement (TMVR) in primary MR will likely be quite limited. Secondary or functional MR is due to a disease of the left ventricle and not the valve itself. The MR is a result of dilation of the left ventricle causing distraction of the papillary muscles with tethering of the mitral leaflets and lack of leaflet coaptation. Medical therapy is the mainstay treatment, with resynchronization used in appropriate patients. Surgical repair, usually with an undersized annuloplasty, is used in a limited number of patients. Transcatheter edge to edge repair is used extensively outside the US in secondary MR and is the subject of a pivotal trial in the US. However, it is in this group of patients with secondary MR that there is the largest clinical unmet need and, hence, the greatest potential opportunity for TMVR. At least ten TMVR platforms are in early feasibility, first in human, or preclinical trial stages. Four devices have cumulative early human experience in <100 patients. In this article, we discuss those patients most likely to benefit from TMVR and detail lessons learned from the first human studies regarding patient selection.

KW - Anatomy

KW - Mitral valve insufficiency

KW - Surgical procedures, operative

UR - http://www.scopus.com/inward/record.url?scp=84990060960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990060960&partnerID=8YFLogxK

M3 - Review article

C2 - 27028332

AN - SCOPUS:84990060960

VL - 57

SP - 352

EP - 359

JO - Journal of Cardiovascular Surgery

JF - Journal of Cardiovascular Surgery

SN - 0021-9509

IS - 3

ER -